Neutroplast launches novel drug-delivery device.

Neutroplast has launched an innovative product directed at women’s health, a vaginal drug delivery device with which the company hopes to revolutionize the segment.

After a detailed study of the market offering Neutroplast concluded that there was a lack of offer for such a hygienic, comfortable and sensitive product and that the blunt objects offered by other manufacturers weren’t user friendly enough, nor provided an adequate compliance to the drug delivery process.

This patent-pending drug-delivery device has thus been designed around bringing maximum ease of use, comfort and efficiency for the delivery of ovules, vaginal pills and creams. It features an ergonomic format together with an innovative release system that allows for the handling of the device with one hand only, maximizing the results both in compliance of the administration as well as in comfort for the user.

As this is a single use, disposable item, cost efficiency was also a concern, therefore the delivery device is built using injection moulded plastic parts, allowing for competitive prices, thus allowing pharmaceutical companies to launch their products using this new technology without hampering commercial results.

Neutroplast S.A. is an ISO 9001:2008 certified Portuguese company that specializes in the production of plastic primary packaging and dosage devices for the healthcare and pharmaceutical markets. It is a family owned SME focused on catering to niche markets in the pharmaceutical industry and its presence ranges from Europe and the North of Africa to the Middle-East and the GCC.